These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10351191)

  • 1. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.
    Ackerman SJ; Sullivan EM; Beusterien KM; Natter HM; Gelinas DF; Patrick DL
    Pharmacoeconomics; 1999 Feb; 15(2):179-95. PubMed ID: 10351191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
    Ginsberg G; Lowe S
    Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.
    Beauverd M; Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2012 Nov; 11():CD002064. PubMed ID: 23152212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
    Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
    Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
    Lai EC; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Murphy MF; Natter HM; Norris FH; Rudnicki SA
    Neurology; 1997 Dec; 49(6):1621-30. PubMed ID: 9409357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease.
    Vaught JL; Contreras PC; Glicksman MA; Neff NT
    Ciba Found Symp; 1996; 196():18-27; discussion 27-38. PubMed ID: 8866126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of early noninvasive ventilation for ALS patients.
    Gruis KL; Chernew ME; Brown DL
    BMC Health Serv Res; 2005 Aug; 5():58. PubMed ID: 16131401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.
    Hirschberg R; Kopple J; Lipsett P; Benjamin E; Minei J; Albertson T; Munger M; Metzler M; Zaloga G; Murray M; Lowry S; Conger J; McKeown W; O'shea M; Baughman R; Wood K; Haupt M; Kaiser R; Simms H; Warnock D; Summer W; Hintz R; Myers B; Haenftling K; Capra W
    Kidney Int; 1999 Jun; 55(6):2423-32. PubMed ID: 10354291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.
    Lange DJ; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Lai EC; Murphy MF; Natter HM; Norris FH; Rudnicki S
    Neurology; 1996 Oct; 47(4 Suppl 2):S93-4; discussion S94-5. PubMed ID: 8858058
    [No Abstract]   [Full Text] [Related]  

  • 19. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
    Clark RG
    Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.